Role of Urothelial Cells in BCG Immunotherapy for Bladder Cancer
Author Information
Author(s): Bevers R F M, Kurth K-H, Schamhart D H J
Primary Institution: Leiden University Medical Center and Academic Medical Center
Hypothesis
The interaction between Bacillus Calmette-Guérin (BCG) and urothelial cells plays a significant role in the efficacy of BCG immunotherapy for bladder cancer.
Conclusion
BCG immunotherapy activates the immune response against bladder cancer, particularly in high-grade tumors, but many details of its mechanism remain unclear.
Supporting Evidence
- BCG is superior to chemotherapy for patients at intermediate to high risk of bladder cancer recurrence.
- High recurrence rates of bladder cancer necessitate ongoing treatment and follow-up.
- BCG treatment can cause side effects, including infections and cystitis.
Takeaway
BCG treatment helps the body fight bladder cancer by making the immune system stronger, especially in more serious cases.
Methodology
This review summarizes existing research on the mechanisms of BCG immunotherapy and the role of urothelial cells in this process.
Limitations
The review highlights that many aspects of BCG's mechanism of action are still not fully understood.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website